These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14715550)

  • 1. Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator.
    Romero-Steiner S; Spear W; Brown N; Holder P; Hennessy T; Gomez De Leon P; Carlone GM
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):89-93. PubMed ID: 14715550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high throughput serum bactericidal assay for antibodies to Haemophilus influenzae type b.
    Kim HW; Kim KH; Kim J; Nahm MH
    BMC Infect Dis; 2016 Sep; 16(1):473. PubMed ID: 27595992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection.
    Townsend K; Ladhani SN; Findlow H; Borrow R
    Vaccine; 2014 Sep; 32(43):5650-6. PubMed ID: 25138290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype a.
    Rouphael NG; Satola S; Farley MM; Rudolph K; Schmidt DS; Gomez-de-León P; Robbins JB; Schneerson R; Carlone GM; Romero-Steiner S
    Clin Vaccine Immunol; 2011 Feb; 18(2):243-7. PubMed ID: 21177919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum bactericidal activity of autologous serum in C2 deficiency after vaccination against Haemophilus influenzae type b, and further support for an MBL-dependent C2 bypass mechanism.
    Jönsson G; Hansson C; Mellhammar L; Gullstrand B; Bengtsson AA; Sahl C; Skattum L
    Vaccine; 2021 Feb; 39(8):1297-1302. PubMed ID: 33509693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against
    Muri L; Schubart A; Thorburn C; Zamurovic N; Holbro T; Kammüller M; Pluschke G; Ispasanie E
    Front Immunol; 2022; 13():1020580. PubMed ID: 36578495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Children with Haemophilus influenzae type b (Hib) vaccine failure have long-term bactericidal antibodies against virulent Hib strains with multiple capsular loci.
    Townsend-Payne K; Ladhani SN; Findlow H; Slack M; Borrow R
    Vaccine; 2016 Jul; 34(34):3931-4. PubMed ID: 27317452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serum bactericidal and antibody titers induced by two Haemophilus influenzae type b conjugate vaccines: A phase III randomized double-blind study.
    Akeda Y; Koizumi Y; Takanami Y; Sumino S; Hattori Y; Sugizaki K; Mitsuya N; Oishi K
    Vaccine; 2018 Mar; 36(12):1528-1532. PubMed ID: 29459064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
    Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
    Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
    J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
    Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
    Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.
    Baggett HC; Hennessy TW; Bulkow L; Romero-Steiner S; Hurlburt D; Holder P; Parkinson AJ; Singleton RJ; Levine O; Carlone GM; Butler JC
    Clin Vaccine Immunol; 2006 Jun; 13(6):620-6. PubMed ID: 16760318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.
    Mountzouros KT; Howell AP
    J Clin Microbiol; 2000 Aug; 38(8):2878-84. PubMed ID: 10921943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.
    Borrow R; Aaberge IS; Santos GF; Eudey TL; Oster P; Glennie A; Findlow J; Høiby EA; Rosenqvist E; Balmer P; Martin D
    Clin Diagn Lab Immunol; 2005 Aug; 12(8):970-6. PubMed ID: 16085915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 18. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
    Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate).
    Romero-Steiner S; Fernandez J; Biltoft C; Wohl ME; Sanchez J; Feris J; Balter S; Levine OS; Carlone GM
    Clin Diagn Lab Immunol; 2001 Nov; 8(6):1115-9. PubMed ID: 11687449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-polyribosylribitol phosphate antibody in pediatric patients with Haemophilus influenzae type b invasive disease.
    Ishiwada N; Honda Y; Tanaka J; Hishiki H; Kohno Y
    J Infect Chemother; 2011 Jun; 17(3):397-400. PubMed ID: 21188446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.